Advanced Filters
noise

Solid Tumor Clinical Trials

A listing of Solid Tumor medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 1,573 clinical trials
D Daan Knapen, MD

Open Label Phase 2 Basket Trial With Atezolizumab and Tiragolumab in Solid Tumors

In this open label phase II trial combination therapy with the anti-PD-L1 antibody atezolizumab and the anti-TIGIT antibody tiragolumab will be investigated in patients with localized HNSCC who will undergo surgery, advanced or metastatic MSI-H cancer, PD-1 resistant metastatic melanoma, and patients with a locally advanced or metastatic solid tumor …

18 years of age All Phase 2
P Peng Wang, M.D.

Cryoablation Combined With Tislelizumab Plus Lenvatinib In Previously Treated Solid Tumors (CASTLE-11)

The objective of this study is to evaluate the efficacy and safety of cryoablation combined with Tislelizumab plus Lenvatinib for patients with previously treated solid tumors.

18 years of age All Phase 2
X Xiaorong Dong, PHD

Phase 1/2 Study of HS-10370 in Patients With Advanced Solid Tumors

HS-10370 is an oral, highly selective, small molecular inhibitor of KRAS G12C. This study will evaluate the safety, tolerability, pharmacokinetics and clinical activity of HS-10370 in Chinese advanced solid tumor patients.

18 years of age All Phase 1/2

Phase 1/2a Study of MPB-1734 in Patients With Advanced Solid Tumors

This is a first-in-human (FIH), multicenter, open-label, uncontrolled, Phase 1/2a study with dose escalation in patients with advanced solid tumors (Part 1) and cohorts of up to 15 patients per selected indication (Part 2). The solid tumor types in Part 2 will be decided by the sponsor prior to the …

18 years of age All Phase 1/2
J Jin Li, Doctor

A Study Evaluating TJ210001 in the Treatment of Subjects With Advanced Solid Tumors

A phase I clinical study evaluating TJ210001 in the treatment of subjects with advanced solid tumors

18 years of age All Phase 1

A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors

The purpose of this trial is to evaluate the safety, tolerability, pharmacokinetics (PK), anti-tumor activity and immunogenic potential of GEN1286 in participants with advanced solid tumors. This trial consists of 2 parts: Part A: Dose escalation and dose level expansion Part B: Tumor-specific expansion with dose optimization

18 years of age All Phase 1/2
X Xingchen Peng, Ph.D

a Polyphenol Whole Tumor Cell Vaccine in Patients With Advanced Malignant Solid Tumors

This project intends to carry out phase I clinical studies on the basis of the previous work, initially exploring the possible effective dose, evaluating its safety and tolerability, with a view to achieving long-term control of the disease, which is expected to provide more options for the treatment of patients …

18 - 65 years of age All Phase 1

First in Human Study of TUB-030 in Patients With Advanced Solid Tumors

The goal of this clinical trial is to learn if the drug TUB-030 works to treat solid cancer in adults. The study will also explore the safety of TUB-030. The main questions it aims to answer are: To determine the safety and tolerability of TUB-030 To determine the maximum tolerated …

18 years of age All Phase 1/2
S Shanzhi Gu

A Phase I Study of SHR-4712 in Patients With Advanced Solid Tumors

This is a Phase 1, open label, first-in-human study to evaluate safety, tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), immunogenicity and anti-tumor activity of SHR-4712 in patients with advanced solid tumors. Patients will treat with SHR-4712 until unacceptable toxicity or disease progression.

18 - 75 years of age All Phase 1
M Marie Asay

A Study of LP-284 in Relapsed or Refractory Lymphomas and Solid Tumors

The goal of this clinical trial is to evaluate the safety and tolerability of escalating doses of LP-284 and to determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D) in patients with relapsed or refractory (R/R) lymphomas and solid tumors. The secondary objectives are to characterize …

18 years of age All Phase 1

Simplify language using AI